GlassScriptPhysician profile
Mausam A Patel
NPI 1619339868
$3,298.53
in general payments reported to CMS, 2019-2025
18 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $120 · 2023: $1,286 · 2024: $1,475 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,178.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $1,206.40 | 2022-2025 | Optune, Optune Lua (Novottf-200t), Optune Gio |
| Astrazeneca Pharmaceuticals LP | $358.82 | 2023-2024 | Lynparza |
| Daiichi Sankyo INC. | $221.99 | 2023 | Enhertu |
| Stemline Therapeutics INC. | $162.28 | 2023-2024 | Orserdu, Elzonris |
| Takeda Pharmaceuticals U.S.A., INC. | $124.27 | 2024 | Fruzaqla |
| Genentech, INC. | $119.70 | 2023 | |
| Emd Serono, INC. | $106.29 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $102.23 | 2023 | Libtayo |
| Agios Pharmaceuticals, INC. | $101.29 | 2023 | Pyrukynd |
| Genentech USA, INC. | $100.87 | 2023 | Tecentriq |
| Sumitomo Pharma America, INC. | $100.84 | 2024 | Orgovyx |
| Janssen Biotech, INC. | $100.67 | 2024 | Rybrevant |
| Sobi, INC | $99.33 | 2024 | |
| Genzyme Corporation | $85.54 | 2024 | |
| Karyopharm Therapeutics INC. | $85.17 | 2023 | Xpovio |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $82.68 | 2024 | Yondelis |
| Intuitive Surgical, INC. | $76.92 | 2024 | |
| Alnylam Pharmaceuticals INC. | $63.24 | 2024 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mausam Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.